How Survodutide Differs from Other Dual Agonists

Survodutide

62% MASH Resolution

In a Phase 2 trial, 62% of MASH patients on survodutide 4.8 mg achieved histologic improvement with no worsening of fibrosis, versus 14% on placebo.

Sanyal et al., NEJM, 2024

Sanyal et al., NEJM, 2024

View as image

Four peptide-based drugs now target more than one metabolic receptor. Tirzepatide pairs GLP-1 with GIP. Mazdutide pairs GLP-1 with glucagon. Survodutide also pairs GLP-1 with glucagon. Retatrutide activates all three. The fact that survodutide and mazdutide share the same receptor combination makes their differences in development strategy, clinical focus, and early data particularly revealing. For survodutide's full clinical profile and mechanism, see the pillar article on survodutide as the dual GLP-1/glucagon agonist targeting your liver.

This article examines what sets survodutide apart from its mechanistic twin (mazdutide), its closest competitor with a different mechanism (tirzepatide), and the triple agonist that extends the concept further (retatrutide).

Survodutide vs Mazdutide: Same Receptors, Different Drugs

Survodutide (BI 456906, Boehringer Ingelheim/Zealand Pharma) and mazdutide (IBI362, Innovent Biologics/Eli Lilly) both activate the GLP-1 receptor and the glucagon receptor. They share the fundamental pharmacological concept: reduce appetite through GLP-1 while increasing energy expenditure and hepatic fat oxidation through glucagon. The differences lie in molecular design, receptor potency balance, clinical development strategy, and regulatory geography.

Molecular structure

Survodutide is derived from glucagon itself, with modifications to add GLP-1R activity and a C18 fatty diacid side chain for albumin binding and once-weekly dosing.^[1] Mazdutide is a modified peptide with fatty acid acylation, also engineered for once-weekly injection, but built from a different starting scaffold. The structural differences affect how each molecule distributes between GLP-1R and GCGR potency.

Receptor potency ratio

The ratio of GLP-1 to glucagon receptor activity is the key pharmacological parameter for any dual agonist. A higher glucagon component drives more liver fat reduction and energy expenditure but increases the risk of glucose elevation. A higher GLP-1 component provides stronger appetite suppression and glucose lowering.

Survodutide's preclinical profiling showed it has moderate potency at both receptors, with the glucagon component calibrated to avoid clinically significant hyperglycemia when combined with GLP-1R activity.^[1] Mazdutide's ratio was optimized for a different balance. Without head-to-head receptor binding data in comparable assay conditions, the exact differences in potency ratios remain unclear from published data.

Clinical focus

The most significant difference is strategic. Survodutide is being developed primarily as a liver disease drug. Its lead indication is MASH, with FDA Breakthrough Therapy Designation and Phase 2 biopsy data showing 62% histologic improvement.^[2] The SYNCHRONIZE Phase 3 program includes both obesity trials and dedicated MASH trials.

Mazdutide is positioned primarily as a weight loss and diabetes drug. Its Phase 3 program (GLORY and DREAMS) focuses on body weight reduction and glycemic control, with liver fat as a secondary endpoint. Mazdutide's 73.3% liver fat reduction in Phase 2 is comparable to survodutide's liver effects, but Innovent has not yet announced biopsy-confirmed MASH trials.

Regulatory and geographic positioning

Mazdutide is approved in China (NMPA, 2025) for weight management and type 2 diabetes. Survodutide has no regulatory approvals yet but has FDA Breakthrough Therapy Designation for MASH, signaling prioritized US review if Phase 3 results support an application. Survodutide's Phase 2 obesity trial spanned 12 countries across multiple continents, giving it a geographic diversity of clinical data that mazdutide (tested only in Chinese populations) lacks.^[3]

For mazdutide's comparison to other Western-developed metabolic peptides, see How Mazdutide Compares to Western-Developed Metabolic Peptides.

Survodutide vs Tirzepatide: Glucagon vs GIP

Tirzepatide (Mounjaro/Zepbound, Eli Lilly) activates GLP-1 and GIP receptors. Survodutide activates GLP-1 and glucagon receptors. Both are dual agonists that outperform single GLP-1 drugs, but through fundamentally different second-receptor mechanisms.

What GIP does that glucagon does not

GIP receptor activation enhances glucose-dependent insulin secretion, promotes nutrient uptake into adipose tissue, and may influence bone metabolism and central appetite regulation. GIP agonism at supraphysiological doses has been linked to weight loss through mechanisms that are incompletely characterized but appear to involve central nervous system effects distinct from GLP-1.

Tirzepatide's GIP component does not produce direct hepatic fat oxidation. Its liver fat reduction comes indirectly through weight loss and improved insulin sensitivity. In SURMOUNT-1, tirzepatide 15 mg produced 22.5% weight loss at 72 weeks, exceeding survodutide's Phase 2 maximum of 14.9% at 46 weeks.^[3]

What glucagon does that GIP does not

Glucagon receptor activation directly stimulates hepatic beta-oxidation, burning stored liver fat as fuel. This direct hepatic effect distinguishes survodutide from tirzepatide on liver disease endpoints. In the Phase 2 MASH trial, survodutide produced biopsy-confirmed histologic improvement in 62% of patients, with liver fat decreasing by at least 30% in 67% of the treatment group.^[2]

Glucagon also increases resting energy expenditure through thermogenesis, an effect that GIP agonism does not produce. This means survodutide attacks obesity from both the intake side (GLP-1 suppresses appetite) and the output side (glucagon increases calories burned at rest).

The tradeoff

Tirzepatide has stronger weight loss data and a longer safety track record. Survodutide has stronger liver disease data and a pharmacological rationale for hepatic indications that tirzepatide cannot match. For patients where liver fat is the primary concern (MASLD, MASH), the GLP-1/glucagon combination has a mechanistic advantage. For pure weight loss, tirzepatide's Phase 3 results are currently superior.

Tirzepatide is FDA-approved for both obesity and type 2 diabetes. Survodutide is still in Phase 3 with no approvals. If SYNCHRONIZE results confirm Phase 2 efficacy, survodutide could become the first drug approved specifically for MASH through an incretin-based mechanism.

Survodutide vs Retatrutide: Dual vs Triple

Retatrutide (Eli Lilly) adds a third receptor: it activates GLP-1, GIP, and glucagon simultaneously. Survodutide activates two of these three (GLP-1 and glucagon). Both share glucagon receptor agonism, which gives both drugs direct hepatic fat-burning effects.

In Phase 2, retatrutide 12 mg reduced liver fat by 82.4% at 24 weeks in a MASLD substudy, and 93% of participants achieved normal liver fat at 48 weeks.^[4] Survodutide's MASH data is biopsy-confirmed (the gold standard), while retatrutide's liver data is imaging-based (MRI-PDFF). This methodological difference makes direct comparison of liver efficacy impossible without head-to-head biopsy studies.

Retatrutide's weight loss exceeds survodutide's. Phase 3 TRIUMPH-4 data showed 28.7% weight loss at 68 weeks. Survodutide's Phase 2 maximum was 14.9% at 46 weeks, though the SYNCHRONIZE Phase 3 program will provide longer-duration data at optimized doses.

The key question for survodutide versus retatrutide is whether adding GIP receptor agonism (making it triple) produces proportionally better outcomes than the dual GLP-1/glucagon approach alone. Retatrutide's superior weight loss may come from GIP, from higher glucagon potency, from its unique potency ratios, or from interaction effects that cannot be attributed to any single receptor. Retatrutide also carries a novel safety signal (dysesthesia at 20.9% on the 12 mg dose) that survodutide has not reported.

For the full mechanism of triple agonism, see How Retatrutide Targets Three Receptors at Once.

Weight Loss Data: Where Survodutide Stands

A meta-analysis of 1,029 participants across 18 treatment arms from survodutide trials found a mean weight reduction of 8.33 kg versus placebo, with effects strengthening at doses above 2 mg/week and treatment durations beyond 16 weeks.^[5]

In the Phase 2 obesity trial (le Roux et al., Lancet Diabetes & Endocrinology, 2024), survodutide's dose-response curve showed weight loss of 6.2% at 0.6 mg up to 14.9% at 4.8 mg over 46 weeks.^[3] Over half of participants on the highest dose lost at least 15% of body weight.

In people with type 2 diabetes, survodutide at doses of 1.8 mg or higher per week produced greater bodyweight reductions than semaglutide, along with clinically meaningful HbA1c reductions of up to 18.38 mmol/mol.^[6]

These numbers are competitive with semaglutide 2.4 mg (14.9% at 68 weeks in STEP-1) but trail tirzepatide 15 mg (22.5% at 72 weeks in SURMOUNT-1) and retatrutide 12 mg (24.2-28.7% in Phase 2/3). Survodutide's Phase 3 SYNCHRONIZE data will clarify whether optimized dosing and longer treatment can close this gap.

For the full breakdown of survodutide's weight loss and metabolic data, see Survodutide Clinical Trial Data.

Safety Comparison: The GI Tolerability Gap

Gastrointestinal side effects are the primary safety concern for all incretin-based drugs, but the severity varies substantially.

In the Phase 2 MASH trial, survodutide produced nausea in 66%, diarrhea in 49%, and vomiting in 41% of patients on the 4.8 mg dose, leading to a 20% discontinuation rate due to adverse events.^[2] This is notably higher than other drugs in the class:

The 20% discontinuation rate in survodutide's MASH trial is the highest among all dual and triple agonists. This may reflect the patient population (MASH patients with existing liver disease may be more GI-sensitive), the dose-escalation protocol, or inherent differences in survodutide's tolerability profile. If SYNCHRONIZE Phase 3 results show a similar discontinuation rate, it could limit survodutide's competitiveness in the obesity market even if efficacy is strong.

The MASH population context matters. Patients with advanced liver disease may metabolize drugs differently, have pre-existing GI symptoms, and tolerate GI-active peptides poorly. Survodutide's GI profile in the obesity trial (SYNCHRONIZE-1, non-MASH population) will provide a cleaner comparison.

For the broader GLP-1 class safety profile, see GLP-1 Side Effects: What to Expect.

The MASH Positioning: Survodutide's Distinctive Niche

Survodutide's strongest differentiator is its MASH data. MASH affects an estimated 5-7% of the global population and is the fastest-growing indication for liver transplantation. Until recently, only resmetirom (approved 2024 for MASH with fibrosis) had regulatory approval. The market has room for multiple agents.

The biopsy-confirmed data from the Phase 2 NEJM trial positions survodutide uniquely among incretin-based drugs. Tirzepatide has imaging-based liver fat data but no published biopsy results in MASH. Retatrutide has imaging data (MRI-PDFF) but not yet biopsy confirmation. Mazdutide has Phase 2 imaging data showing 73.3% liver fat reduction but no MASH-specific trial.

Survodutide is the only drug in this class with FDA Breakthrough Therapy Designation for MASH. If Phase 3 biopsy data confirms Phase 2 results, survodutide could carve out a liver-specific niche that other dual agonists cannot easily replicate. The combination of metabolic weight loss and direct hepatic fat clearance through glucagon agonism is pharmacologically suited to MASH in a way that GLP-1/GIP dual agonists are not.

For the full MASH evidence and context, see Survodutide and MASH: Why This Drug Focuses on Liver Fat.

The Bottom Line

Survodutide shares the GLP-1/glucagon receptor mechanism with mazdutide but differs in molecular structure, clinical focus, and regulatory positioning. Survodutide targets MASH as its lead indication (with FDA Breakthrough Therapy Designation and biopsy-confirmed Phase 2 data), while mazdutide focuses on weight loss and diabetes in Chinese populations. Compared to tirzepatide (GLP-1/GIP), survodutide's glucagon component provides direct hepatic fat oxidation that GIP agonism cannot match. Phase 3 SYNCHRONIZE results expected in 2026 will determine survodutide's commercial viability in a competitive landscape.

Frequently Asked Questions

What is the difference between survodutide and mazdutide?

Both activate GLP-1 and glucagon receptors, but they are different molecules with different structures, potency ratios, and clinical strategies. Survodutide is derived from glucagon and focuses on MASH as its lead indication with FDA Breakthrough Therapy Designation. Mazdutide is approved in China for weight management and diabetes. Survodutide has global Phase 2 data across 12 countries; mazdutide has only been tested in Chinese populations.

Is survodutide better than tirzepatide for liver disease?

Survodutide has a pharmacological advantage for liver disease because its glucagon receptor component directly stimulates hepatic fat oxidation. In Phase 2, 62% of MASH patients on survodutide achieved histologic improvement (Sanyal et al., NEJM, 2024). Tirzepatide reduces liver fat indirectly through weight loss. For pure liver fat endpoints, the GLP-1/glucagon mechanism has a stronger mechanistic rationale than GLP-1/GIP.

How much weight can you lose on survodutide?

In Phase 2, survodutide 4.8 mg produced up to 14.9% weight loss at 46 weeks in adults with obesity across 12 countries (le Roux et al., Lancet Diabetes & Endocrinology, 2024). Over half of participants on the highest dose lost at least 15% body weight. Phase 3 SYNCHRONIZE results, expected in 2026, will provide longer-duration efficacy data.

What are the side effects of survodutide?

Gastrointestinal symptoms are the primary concern. In the MASH Phase 2 trial, nausea affected 66%, diarrhea 49%, and vomiting 41% of patients on survodutide 4.8 mg, with 20% discontinuing treatment due to adverse events (Sanyal et al., NEJM, 2024). These rates are higher than reported for tirzepatide, semaglutide, or mazdutide, though the MASH patient population may partly explain the difference.

When will survodutide be approved?

Survodutide has not been approved in any market as of early 2026. Phase 3 SYNCHRONIZE-1 and SYNCHRONIZE-2 trials are fully enrolled with results expected in the first half of 2026. If results are positive, Boehringer Ingelheim could file for FDA approval in 2026-2027. The FDA Breakthrough Therapy Designation for MASH may accelerate the review process.

How does survodutide compare to retatrutide?

Retatrutide activates three receptors (GLP-1, GIP, and glucagon) while survodutide activates two (GLP-1 and glucagon). Both share glucagon-mediated liver fat effects. Retatrutide produces greater weight loss (28.7% in Phase 3 vs survodutide's 14.9% in Phase 2). Survodutide has biopsy-confirmed MASH data, while retatrutide's liver data uses imaging only. Retatrutide has a dysesthesia safety signal (20.9% at 12 mg) not seen with survodutide.